KORU Medical Systems, Inc. (NASDAQ:KRMD) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• KORU Medical Systems, Inc. has received a consensus recommendation of "Moderate Buy" from six analysts, with an average price target of $4.6250.
• The company reported positive earnings of $0.01 per share for the last quarter, exceeding analyst expectations of ($0.03).
• Institutional investors and hedge funds own 58.60% of KORU Medical Systems' stock, indicating strong backing from larger financial entities.

Shares of KORU Medical Systems, Inc. (NASDAQ:KRMD - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $4.6250.

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of KORU Medical Systems in a research report on Saturday, September 27th.

KORU Medical Systems Stock Up 1.9%

Shares of KORU Medical Systems stock traded up $0.07 on Friday, hitting $3.85. 43,032 shares of the company traded hands, compared to its average volume of 182,736. The company has a quick ratio of 2.25, a current ratio of 2.91 and a debt-to-equity ratio of 0.01. KORU Medical Systems has a 12-month low of $1.86 and a 12-month high of $5.05. The company has a 50-day moving average price of $3.95 and a 200 day moving average price of $3.29. The company has a market cap of $178.02 million, a PE ratio of -42.78 and a beta of 0.49.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.04. KORU Medical Systems had a negative net margin of 12.24% and a negative return on equity of 26.77%. The business had revenue of $10.20 million during the quarter, compared to analyst estimates of $9.46 million. Sell-side analysts predict that KORU Medical Systems will post -0.13 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. White Pine Capital LLC raised its position in shares of KORU Medical Systems by 1.6% during the second quarter. White Pine Capital LLC now owns 225,425 shares of the company's stock valued at $807,000 after buying an additional 3,526 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of KORU Medical Systems by 11.8% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 66,917 shares of the company's stock valued at $170,000 after buying an additional 7,046 shares during the last quarter. HighTower Advisors LLC raised its position in shares of KORU Medical Systems by 18.4% during the first quarter. HighTower Advisors LLC now owns 51,400 shares of the company's stock valued at $131,000 after buying an additional 8,000 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of KORU Medical Systems during the second quarter valued at about $30,000. Finally, Millennium Management LLC raised its position in shares of KORU Medical Systems by 4.5% during the fourth quarter. Millennium Management LLC now owns 283,710 shares of the company's stock valued at $1,092,000 after buying an additional 12,187 shares during the last quarter. Institutional investors and hedge funds own 58.60% of the company's stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.